Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Multiple Research Teams Unable to Confirm High-Profile Alzheimer’s Study

Published: Friday, May 24, 2013
Last Updated: Friday, May 24, 2013
Bookmark and Share
Teams of highly respected Alzheimer’s researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.

Those results, presented online Feb. 9, 2012, suggested that the drug bexarotene (marketed as Targretin) could rapidly reverse the buildup of beta amyloid plaques (Aβ)—a pathological hallmark of Alzheimer’s disease—in the brains of mice. According to the authors of the 2012 report, drug treatment quickly removed most of the plaques and brought rapid reversal of the pathological, cognitive and memory deficits related to the onset of Alzheimer’s.

However, the new reports from extensive and carefully controlled studies did not show any reduction in the number of plaques or total area occupied by the plaques during or after treatment. These results are described in three “technical comments”—one of which comes from researchers at the University of Chicago, Northwestern University, Massachusetts General Hospital, Washington University in St. Louis and the University of Tubingen in Germany—to be published in the May 24 issue of Science.

“The drug has no impact on plaque burden in three strains that exhibit Aβ amyloidosis,” according to that group's comment. “We have failed to support earlier findings by Cramer et al that Targretin is efficacious in reducing plaque burden in transgenic mouse models of cerebral Aβ deposition.”

Comment co-author Sangram Sisodia, professor of neurosciences at the University of Chicago, said he and his colleagues were curious about the initial report in 2012.

“We were surprised and excited, even stunned, when we first saw these results presented at a small conference,” said Sisodia. “The mechanism of action made some sense, but the assertion that they could reduce the areas of plaque by 50 percent within three days, and by 75 percent in two weeks, seemed too good to be true.”

“We all went back to our labs and tried to confirm these promising findings,” Sisodia added. “We repeated the initial experiments—a standard process in science. Combined results are really important in this field. None of us found anything like what they described in the 2012 paper.”

The researchers found no effects on plaque burden in three different strains of mice that were treated with bexarotene.

The discrepancy, besides being disappointing, also raises concerns about patient safety. The Food and Drug Administration approved bexarotene in December 1999 for a very specific use: treatment of refractory cutaneous T-cell lymphoma, a type of skin cancer. Once approved, the drug became legally available by prescription for “off-label” uses as well.

“Anecdotally, we have all heard that physicians are treating their Alzheimer's patients with bexarotene, a cancer drug with severe side effects,” said co-author Robert Vassar, professor of cell and molecular biology at Northwestern University Feinberg School of Medicine. “This practice should be ended immediately, given the failure of three independent research groups to replicate the plaque-lowering effects of bexarotene.”

Bexarotene has never been tested as a treatment for Alzheimer’s disease in humans, not even to determine the optimal dose or duration of treatment. This drug has significant side effects, including major blood-lipid abnormalities, pancreatitis, liver function test abnormalities, thyroid axis alterations, leucopenia, headaches, fatigue, weight gain, depression, nausea, vomiting, constipation and rash.

The two other technical comments came from research teams led by Kevin Felsenstein, Todd Golde, David Borchelt and colleagues at the University of Florida, and by Bart DeStrooper and colleagues at the University of Leuven, Belgium.

There is no cure or effective treatment for Alzheimer’s disease, which is a progressive type of dementia that occurs when nerve cells in the brain die. When Alzheimer’s was first identified in 1906, it was considered a rare disorder. Today, Alzheimer’s is the most common cause of dementia; an estimated 5.3 million Americans have the disease.

This work was supported by the Cure Alzheimer’s Fund. Additional authors include Karthikeyan Veeraraghavalu of the University of Chicago; Rudolph Tanzi, Can Zhang and Sean Miller of Massachusetts General Hospital; Jasmin K. Hefendehl and Mathias Jucker of the University of Tübingen; Tharinda W. Rajapaksha and Robert Vassar of Northwestern University Feinberg School of Medicine; and Jason Ulrich and David M. Holtzman from the Washington University School of Medicine.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Manipulation of Liquid Crystals Could Help Control Drug-Delivery Process
Computer modeling, real-world testing yields new method.
Wednesday, September 14, 2016
Liquid Crystal Manipulation Controls Drug-Delivery Process
Scientists have turned liquid crystals into a tool to control the shape of synthetic cell membranes.
Tuesday, September 13, 2016
Grad Student's Finding Enables Rapid Compound Screening
Grad student makes technical leap that could enable rapid screening of anti-cancer compounds.
Friday, August 19, 2016
From Fins to Fingers
New gene-editing methods help the mapping of cells linking fish fins and mammalian limbs.
Friday, August 19, 2016
New Technique Targets Ataxia Gene
Scientists selectively turn off the disease-causing portion of a gene that causes a severe form of ataxia.
Thursday, July 14, 2016
Organ Behaviour Manipulation Possible with New Injectable
Scientists develop injectable that could be used to stimulate nerve cells and manipulate muscle and organ behaviour.
Friday, July 08, 2016
New Microbiome Center to Merge Expertise of UChicago, MBL and Argonne
Researchers to study world of microbes across environments.
Wednesday, May 18, 2016
AbbVie, University of Chicago Collaborate
The University of Chicago and AbbVie have entered into a five-year collaboration agreement designed to improve the pace of discovery and advance medical research in oncology at both organizations.
Thursday, April 21, 2016
New Code for Control of Gene Expression
A new cellular signal discovered by a team of scientists at the University of Chicago and Tel Aviv University provides a promising new lever in the control of gene expression.
Thursday, February 18, 2016
Bacterial Circadian Clocks Set by Metabolism, Not Light
New study finds that metabolism is the primary driver of the circadian rhythm.
Monday, December 14, 2015
New Nanomanufacturing Technique Advances Imaging, Biosensing Technology
Researchers invent a novel way to build nanolenses in large arrays using a combination of chemical and lithographic techniques.
Thursday, December 10, 2015
Enormous Genetic Variation May Shield Tumors from Treatment
Debate over Darwinian selection vs. random mutations emerges at the tumor level.
Wednesday, November 11, 2015
Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy
Manipulating microbes maximizes tumor immunity in mice.
Monday, November 09, 2015
Protein Aggregation After Heat Shock Is An Organized, Reversible Response
New study finds protein aggregation after heat exposure is a reversible cellular process, not unrecoverable damage from misfolding.
Friday, September 11, 2015
New Form of DNA Modification May Carry Inheritable Information
Scientists have described the surprising discovery and function of a new DNA modification in insects, worms and algae.
Friday, May 08, 2015
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Modified Yeast Shows Plant Response to Key Hormone
Researchers have developed a toolkit based on modified yeast to determine plant responses to auxin.
Adipose Tissue Secretes Factors That Activate Metabolism
Study finds brown adipose tissue secretes signalling factors that activates metabolism of fat and carbohydrates.
Antibiotic Resistant Bacteria In America's Water System
Antibiotic resistant bacteria live inside drinking water distribution systems blamed for rising healthcare costs.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Ancient Eggshell Protein Breaks Through DNA Time Barrier
Fossil proteins from a 3.8million year-old eggshell have been identifed, suggests proteins could give insight into evolutionary tree.
Monkeys Protected by Zika DNA Vaccine
Experimental Zika virus DNA vaccines successfully protected monkeys against Zika infection.
Nanosensors Could Determine Tumours’ Ability to Remodel Tissue
Researchers design nanosensors that can profile tumours, focusing on protease levels.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!